Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday, ValuEngine reports.

Separately, Maxim Group restated a “buy” rating and set a $9.00 target price on shares of Brainstorm Cell Therapeutics in a research report on Tuesday, May 14th.

Shares of NASDAQ BCLI traded down $0.10 during midday trading on Thursday, hitting $3.58. The company had a trading volume of 45,400 shares, compared to its average volume of 90,899. The company has a quick ratio of 0.52, a current ratio of 0.52 and a debt-to-equity ratio of 9.34. Brainstorm Cell Therapeutics has a twelve month low of $2.92 and a twelve month high of $4.50. The business has a 50-day simple moving average of $3.93 and a two-hundred day simple moving average of $3.92.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.12). Equities research analysts anticipate that Brainstorm Cell Therapeutics will post -0.68 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Delek Group Ltd. acquired a new position in Brainstorm Cell Therapeutics during the first quarter worth about $183,000. CIBC Private Wealth Group LLC raised its position in Brainstorm Cell Therapeutics by 349.9% during the first quarter. CIBC Private Wealth Group LLC now owns 67,484 shares of the biotechnology company’s stock worth $293,000 after acquiring an additional 52,484 shares during the last quarter. BlackRock Inc. raised its position in Brainstorm Cell Therapeutics by 44.6% during the second quarter. BlackRock Inc. now owns 130,281 shares of the biotechnology company’s stock worth $514,000 after acquiring an additional 40,197 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Brainstorm Cell Therapeutics by 10.7% during the second quarter. Renaissance Technologies LLC now owns 224,377 shares of the biotechnology company’s stock worth $886,000 after acquiring an additional 21,720 shares during the last quarter. Institutional investors own 11.26% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Read More: What is the Producer Price Index (PPI)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.